Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension.
BackgroundSelexipag, an oral IP prostacyclin receptor agonist, improves outcomes in pulmonary arterial hypertension (PAH); however, real-world hemodynamic data and the relationship between adverse events (AEs) and treatment response are limited.ObjectivesThe aims of this study were to evaluate the efficacy and safety o...